iPS Academia Japan, Inc. to Distribute Cellular Dynamics' iCell Products in Japan
Jul 12, 2011Cellular Dynamics International, Inc. (CDI) today announced an agreement with iPS Academia Japan, Inc., who will distribute CDI's iCell® Cardiomyocytes, the first commercially available product based on induced pluripotent stem cells (iPSCs), in Japan. This distribution agreement brings the vision of the two pioneers of iPSC technology, Dr. James Thomson and Dr. Shinya Yamanaka, a step closer to making the technology widely available to researchers worldwide and thus impacting human health and biological research...
Cellular Dynamics International, ACEA Biosciences, and Roche Applied Sciences Cooperate to Evaluate iCell Cardiomyocytes on the xCELLigence System
Oct 12, 2010Cellular Dynamics International (CDI) announced their partnership with ACEA Biosciences to bring early and accurate prediction of potential cardiotoxic side effects to the drug discovery process. The partnership combines CDI's induced pluripotent stem cell (iPSC)-derived heart cells, iCellTM Cardiomyocytes, with the xCELLigenceTM RTCA System. The xCELLigence System is developed by ACEA and Roche Applied Science and marketed by Roche
Cellular Dynamics International, Inc. (CDI) today announced an agreement with iPS Academia Japan, Inc., who will distribute CDI's iCell® Cardiomyocytes, the first commercially available product based on induced pluripotent stem cells (iPSCs), in Japan. This distribution agreement brings the vision of the two pioneers of iPSC technology, Dr. James Thomson and Dr. Shinya Yamanaka, a step closer to making the technology widely available to researchers worldwide and thus impacting human health and biological research...